Fat dissolvers: the regulatory and clinical reality in the UK

|Longeva Pharmacy Clinical Team
A wax-sealed document tied with cord on a desk

Aqualyx remains the only CE-marked injectable lipolytic on the UK market, and that single fact reframes every other product on the shelf.

Practitioners working in medical aesthetics in the UK are regularly approached by suppliers offering injectable fat-dissolving products at competitive prices. Some are well-established, clinically evidenced, and properly licensed. Others occupy a legal grey area at best, and a directly illegal position at worst. This article sets out the regulatory reality as it stands, gives practitioners a defensible framework for product selection, and works through the Lemon Bottle episode as a case study for what happens when that framework is ignored.

What injectable lipolytics are and how they work

Injectable lipolytics are products designed to disrupt and metabolise localised adipose tissue. The two most studied active agents are deoxycholic acid (DCA) and phosphatidylcholine (PPC), often used in combination.

Deoxycholic acid is a naturally occurring bile acid. When injected into subcutaneous fat, it disrupts the integrity of adipocyte cell membranes through a detergent-like action, leading to cell lysis and subsequent inflammation, phagocytosis, and over several weeks, measurable volume reduction (Rotunda AM, Kolodney MS. Dermatologic Surgery, 2006). Phosphatidylcholine is a phospholipid component of cell membranes; evidence for its independent lipolytic mechanism remains less well-characterised in peer-reviewed literature, though many formulations combine it with DCA.

These mechanisms matter from a regulatory standpoint because they determine how the product is classified: a product that achieves its intended purpose primarily through pharmacological means is a medicine, not a device, and must be authorised as such under the Human Medicines Regulations 2012 or hold a CE or UKCA mark under the applicable device regulations.

UK regulatory status: CE marking, medical devices, and why most products are unlicensed

Following the UK's exit from the European Union, the regulatory landscape for medical devices diverged from the EU Medical Device Regulation (MDR 2017/745). The UK now operates under the Medical Devices Regulations 2002 (as amended), with transitional provisions that continue to recognise CE-marked devices on the GB market until their respective deadlines. The MHRA is responsible for post-market surveillance and enforcement.

Aqualyx (Marllor International) holds CE marking as a medical device and has been used by UK practitioners for localised fat reduction in areas including the submental region, abdomen, thighs, and knees. It is the only injectable lipolytic product that currently holds a CE mark recognised in the UK market for this purpose. Browse our fat dissolver range for Aqualyx and related products available to registered practitioners.

DesoBody and DesoFace (Deutsche Aesthetische Pharmazie) are further products used in UK practice. These are CE-marked medical devices intended for larger and smaller volume fat deposits respectively, and they are sourced by practitioners who have verified their regulatory status.

The critical point is that a product being injectable, being widely sold to practitioners, or being described by a supplier as approved does not constitute MHRA authorisation or CE/UKCA compliance. A product that acts pharmacologically must be authorised as a medicine. A product regulated as a device must hold a valid CE or UKCA mark and be registered with the MHRA on the approved database. Any product meeting neither threshold is unlicensed for use in the UK.

The Lemon Bottle case study: what it teaches practitioners

Lemon Bottle became one of the most heavily marketed injectable lipolytic products in the UK between 2022 and 2024, promoted heavily on social media and sold through a range of aesthetic suppliers. It was presented as a lipolytic cocktail containing riboflavin, bromelain, and lecithin. No CE mark was held. No UK product licence existed. Independent testing of batch composition was not published.

In March 2025, the United States Food and Drug Administration issued a warning letter to Fox Pharma LLC in connection with the importation and distribution of Lemon Bottle products, citing concerns about unlicensed drug marketing (FDA warning letter to Fox Pharma LLC, March 2025; available via the FDA warning letters database at fda.gov). While the FDA letter addresses the US context, it is consistent with the MHRA position: products claiming to dissolve fat through pharmacological action require a product licence. The MHRA Yellow Card scheme has received adverse event reports linked to injectable lipolytic products, including inflammatory reactions, nodule formation, and prolonged swelling. Practitioners can submit reports at yellowcard.mhra.gov.uk.

The British College of Aesthetic Medicine (BCAM) has addressed the need for practitioners to verify the regulatory status of products before use. BCAM guidance on injectables underlines that practitioners carry direct clinical and legal accountability for the products they inject, regardless of supplier representations (BCAM guidance on dermal fillers and injectables).

The lesson from Lemon Bottle is not primarily about that one product. It is about the structural risk of a market where any substance can be bottled, named attractively, and sold as a cosmetic injectable in the absence of rigorous enforcement at the point of supply. Practitioners who injected it bore the clinical consequences and the liability.

Practitioner liability and insurance

Under UK law, a practitioner who injects an unlicensed product into a patient assumes the full burden of liability for any resulting harm. This applies whether the practitioner is a medical doctor, nurse prescriber, dentist, or any other regulated clinician. The supplier's representations about a product's safety profile, however detailed, do not transfer liability away from the person who administered the injection.

Most professional indemnity and liability insurers operating in the UK aesthetics sector now include product-licensing exclusions or require practitioners to declare the regulatory status of every product in use. A practitioner injecting an unlicensed product may find their cover invalidated. In the event of a serious adverse event, this exposes them to unindemnified civil liability and potentially to regulatory action from their professional body.

The Advertising Standards Authority has been active in the aesthetics sector. While its primary enforcement focus to date has been on before-and-after imagery and platform-specific advertising rules, the direction of regulatory travel is clearly towards greater scrutiny of product claims and practitioner accountability. The ASA enforcement update on aesthetic advertising provides useful context for practitioners on how this applies to promotional activity (ASA enforcement update: aesthetic treatment advertising).

How to source compliantly

Compliant sourcing for injectable lipolytics in the UK requires practitioners to take three steps before placing any order.

First, verify the regulatory status of the product directly. For a medical device, this means confirming that a valid CE or UKCA mark exists and that the product is registered on the MHRA device register. For a medicine, it means confirming a current product licence number with the MHRA. If neither can be confirmed, the product is unlicensed.

Second, source from a pharmacy or wholesaler operating under a Wholesale Dealer Authorisation granted by the MHRA. A WDA holder is subject to Good Distribution Practice inspections and is required to maintain traceability across the supply chain. Sourcing from unregulated online platforms, social media vendors, or grey-market importers removes this assurance and transfers further liability to the practitioner.

Third, retain batch records. Lot numbers, expiry dates, supplier documentation, and patient treatment records should be kept for a minimum of ten years in line with standard clinical record-keeping guidance. In the event of an adverse event or regulatory inquiry, this documentation is the primary evidence of due diligence. View our full product range for GPhC-registered pharmacy supply of compliant injectables.

Patient selection and safety considerations

Even with a CE-marked product sourced through a licensed pharmacy, appropriate patient selection remains the practitioner's responsibility.

Injectable lipolytics are not appropriate for patients with active infection at the treatment site, autoimmune conditions affecting the skin, pregnancy or breastfeeding, or a body mass index above the range established in the manufacturer's instructions for use. Informed consent must cover the realistic outcome range, the typical inflammatory response (swelling, tenderness, erythema for one to two weeks), the need for multiple sessions, and the possibility of adverse outcomes including prolonged nodule formation.

Aqualyx's instructions for use specify that injections should be administered using the mesotherapy technique, with practitioners trained in both the anatomy of the target region and the management of post-procedural adverse events. DesoBody and DesoFace carry their own manufacturer training and indication guidance, which practitioners should read and retain.

When treating the submental region in particular, practitioners must be confident in their knowledge of the anatomy to avoid inadvertent injection into muscle, gland, or vascular structures. This is a higher-risk treatment zone than many surface areas and is not appropriate for practitioners without specific training in submental anatomy and lipolytic technique.

What to tell patients

Patients receiving fat dissolving injections in a compliant UK practice are entitled to a clear, honest account of the product being used, its regulatory status, what it will and will not achieve, and the realistic timeline and side-effect profile.

The consent process should cover: the product name and its CE-marked or licensed status; the mechanism of action in plain terms; the expected treatment course (typically two to four sessions for Aqualyx, spaced four to six weeks apart); the normal post-treatment response including swelling, bruising, and tenderness; the possibility of incomplete response or requirement for further sessions; and the procedure for reporting adverse events, including via the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk) for unexpected reactions to medical devices.

Practitioners should also be clear about what fat dissolving injections are not. They are not a treatment for generalised obesity. They are not a substitute for medical weight management in patients with significant excess body weight. Positioning them accurately protects both the patient and the practitioner from misaligned expectations and the complaints that follow. Browse our dermal fillers collection for further compliant injectable products available through Longeva Pharmacy.

Key takeaways

  • Aqualyx is the only CE-marked injectable lipolytic on the UK market. DesoBody and DesoFace are also CE-marked options used in UK practice.
  • A product being widely sold or marketed does not mean it holds a CE mark or UK product licence. Practitioners must verify status independently before use.
  • The Lemon Bottle episode and the subsequent FDA warning letter to its US distributor illustrate the consequences of a market where unlicensed products circulate widely and practitioners bear the resulting liability.
  • Professional indemnity cover may be invalidated when unlicensed products are used. Practitioners carry full liability for harm caused by unlicensed injectables they administer.
  • Source only from MHRA WDA-licensed pharmacies or wholesalers and retain batch records for a minimum of ten years.
  • Patient selection, anatomical knowledge, and honest informed consent remain clinical obligations regardless of which licensed product is used.
  • Adverse events should be reported via the MHRA Yellow Card scheme to support post-market surveillance of all injectable devices.

References

Reviewed for clinical accuracy under the supervision of our Superintendent Pharmacist, Alicia Barker (GPhC 2241860). Longeva Pharmacy is a GPhC-registered pharmacy (registration 9012378) operating under MHRA WDA(H) licence 59619. Information is intended for licensed UK practitioners and does not replace individual clinical judgement.